Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661491 · ClinicalTrials.gov registry record
Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 40
- Enrollment target
NCT01661491 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 40 participants.
The verdict
NCT01661491 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of early inflammation and lung damage. This study asks how early acquisition of microbial flora occurs in infants with CF and healthy baby controls, and whether this process initiates or influences early inflammation and clinical disease progression in CF.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-08 |
| Est. Completion | 2020-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01661491
The ClinicalTrials.gov registry entry for NCT01661491 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01661491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01661491 about?
NCT01661491 is a clinical study titled "Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis". Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of ...
What is the current status of trial NCT01661491?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2012-08. Estimated completion is 2020-12.
Who is sponsoring clinical trial NCT01661491?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.